Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 10/20 | 1.00 |
| ▸ | PARP1 | P09874 | 6/20 | 1.00 |
| ▸ | PARP11 | Q9NR21 | 6/20 | 0.74 |
| ▸ | F7 | P08709 | 1/20 | 0.64 |
| ▸ | F3 | P13726 | 1/20 | 0.64 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | TDP2 | O95551 | 2/20 | 0.46 |
| ▸ | PNMT | P11086 | 1/20 | 0.46 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | TYMS | P04818 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29676851 | 1.00 | PARP10 (1.00) | PARP10PARP1PARP11F7F3 | |
| SCHEMBL19838786 | 0.89 | PARP10 (0.81) | PARP10PARP1PARP11F7F3 | |
| SCHEMBL29712442 | 0.89 | PARP10 (0.81) | PARP10PARP1PARP11F7F3 | |
| SCHEMBL1002712 | 0.85 | PARP10 (1.00) | PARP10PARP1PARP11F7F3 | |
| SCHEMBL29438680 | 0.81 | PARP10 (0.69) | PARP10PARP1PARP11F7F3 | |
| SCHEMBL246168 | 0.81 | PARP10 (0.69) | PARP10PARP1PARP11F7F3 | |
| SCHEMBL391991 | 0.81 | PARP10 (0.68) | PARP10PARP1PARP11F7F3 | |
| SCHEMBL29506974 | 0.81 | PARP10 (0.68) | PARP10PARP1PARP11F7F3 | |
| SCHEMBL23952279 | 0.78 | PARP10 (1.00) | PARP10PARP1PARP11F7F3 | |
| SCHEMBL793665 | 0.78 | PARP10 (0.64) | PARP10PARP1PARP11F7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132132-A1 | 3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2026-05-14 | — | — | US | disclosed |
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260035362-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC (CN) | 2026-02-05 | — | — | US | disclosed |
| EP-4630402-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-10-15 | — | — | EP | disclosed |
| US-12365670-B2 | GLP-IR agonists and uses thereof | QILU REGOR THERAPEUTICS INC. (CN) | 2025-07-22 | — | — | US | disclosed |
| WO-2025096856-A1 | COVALENT CEREBLON LIGANDS | C4 THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025090514-A1 | COVALENT SARM1 INHIBITORS | NURA BIO, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| WO-2025026442-A1 | FUSED RING COMPOUND AND USE THEREOF | 郑州同源康医药有限公司 | 2025-02-06 | — | — | WO | disclosed |
| US-20240368136-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-11-07 | — | — | US | disclosed |
| WO-2024153112-A1 | PDE4 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | 瑞石生物医药有限公司 | 2024-07-25 | — | — | WO | disclosed |
| WO-2009036144-A1 | ISOQUINOLINYL AND ISOINDOLINYL DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20090069300-A1 | ISOQUINOLINYL AND ISOINDOLINYL DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090062265-A1 | Pyrrolo-Quinoxalinone Derivatives as Antibacterials | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| EP-2010532-A1 | TRYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2009-01-07 | — | — | EP | disclosed |
| EP-2001887-A1 | PYRROLO-QUINOXALINONE DERIVATIVES AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2008-12-17 | — | — | EP | disclosed |
| EP-1932831-A1 | 1,2-Diarylacetylene Derivatives of Acyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-06-18 | — | — | EP | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| WO-2007122258-A1 | TRYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007115947-A1 | PYRROLO-QUINOXALINONE DERIVATIVES AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2007-10-18 | — | — | WO | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132132-A1 | 3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS | F11, F13B, F7 | PARP10 1988/4885PARP1 462/4885PARP11 294/4885 |
| US-20260035362-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, IAPP | PARP10 4112/4885PARP1 3176/4885PARP11 2171/4885 |
| US-20090069300-A1 | ISOQUINOLINYL AND ISOINDOLINYL DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | HRH4, HRH3, HRH2 | PARP10 2737/4885PARP1 4382/4885PARP11 3376/4885 |
| US-12365670-B2 | GLP-IR agonists and uses thereof | GLP1R, GPR119, GIPR | PARP10 3137/4885PARP1 3888/4885PARP11 3745/4885 |
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | CCR6, CCR1, CCR4 | PARP10 3928/4885PARP1 3091/4885PARP11 2087/4885 |
| US-20090062265-A1 | Pyrrolo-Quinoxalinone Derivatives as Antibacterials | NQO2, PPOX, ASNS | PARP10 825/4885PARP1 400/4885PARP11 1479/4885 |
| US-20240368136-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | PARP10 3573/4885PARP1 1722/4885PARP11 930/4885 |
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | PARP10 1423/4885PARP1 1660/4885PARP11 1472/4885 |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | PARP10 273/4885PARP1 187/4885PARP11 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.